Federal Judge Rules Trump Administration Unlawfully Halted EV Charger Funding 
Supreme Court Tests Federal Reserve Independence Amid Trump’s Bid to Fire Lisa Cook 
Japan’s Agricultural, Forestry and Fishery Exports Hit Record High in 2025 Despite Tariffs 
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House 
New York Judge Orders Redrawing of GOP-Held Congressional District 
U.S. Stock Futures Slip as Markets Brace for Big Tech Earnings and Key Data 
Trump Administration Appeals Judge’s Order Limiting ICE Tactics in Minneapolis 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Oil Prices Steady as Markets Weigh U.S.-Iran Talks, Dollar Strength Caps Gains 
DOJ Urges Judge to Block Lawmakers’ Bid for Special Master in Jeffrey Epstein Records Case 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
India Budget 2025 Highlights Manufacturing Push but Falls Short of Market Expectations 
Gold, Silver, and Platinum Rally as Precious Metals Recover from Sharp Selloff 
Johnson & Johnson disclosed that it spent $800 million in settling "substantially all" of the roughly 9,000 cases by men who claimed having developed excessive breast tissue in using the company's antipsychotic drug Risperdal.
The company said it reached the agreement with lawyers handling the cases, including a lawsuit in Philadelphia by Maryland resident Nicholas Murray, who was awarded an $8 billion in punitive damage by a jury award in 2019. A judge has since reduced the award to $6.8 million.
The lawsuits, filed in Pennsylvania, California, and Missouri, generally accused J&J of failing to warn of the risk called gynecomastia associated with Risperdal, which they claimed were marketed for off-label, unapproved uses with children.
The company denied the allegations.
In 1993, the US Food and Drug Administration approved Risperdal for treating schizophrenia and bipolar mania in adults. It was only in 2006 that it was approved for treating irritability associated with autism in children.
The company separately agreed in 2013 to pay $2.2 billion to settle US criminal and civil probes into its marketing of Risperdal and two other drugs.
In May, the US Supreme Court rejected J&J's bid to overturn a $70 million jury verdict against it for its failure to warn about risks associated with using Risperdal.
